China Universal 800 Health Care ETF

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Increases Holding in Wuxi Biologics H Shares

HSBC Upgrades Wuxi Biologics Rating and Target Price

Goldman Sachs Analyst Gives Buy Rating to WuXi AppTec's H Shares

JPMorgan Raises Target Price for WuXi AppTec to HKD 172

01011

513700

512290

159849

589720

512010

510660

159929

516930

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

Tip Ranks

NT PHARMA

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

00241

Brokers have provided updated ratings and target prices for ALI HEALTH. Citi maintains a 'Buy' rating with a target price of HKD8, citing conservative profit guidance due to reinvestments. BofA Securities also rates it 'Buy' at HKD6, highlighting unexpected dividends. CLSA's 'Outperform' rating drops to HKD4.7, while HSBC Research holds at HKD4.5, noting slowed revenue growth. UBS rates it 'Sell' with a target of HKD3.6, citing missed revenue targets and reduced profit forecasts.

AASTOCKS News

ALI HEALTH

Citigroup

Bank of America

TE HEALTHCARE

HSBC HOLDINGS

HSBC

UBS Group AG

JD HEALTH

CITIGROUP INC 6.250 NON CUM SER II PFD WI

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

HSBC 5xShortSG241213

HSBC Holdings Plc

JD HEALTH-R

Summary of Latest Ratings, TP, Views on ALI HEALTH from Brokers

ZLAB

09688

159570

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

Hwabao WP CSI Pharmaceuticals ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

01833

516610

513120

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

PA GOODDOCTOR

Dacheng CSI All Share Health Care Equipment and Services ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

06618

JD HEALTH and ALI HEALTH shares fell 3%-5% following concerns over new GLP-1 drug sales regulations in Shanghai. CLSA noted that online sales remain unaffected and the impact of potential restrictions would be manageable, as GLP-1 drugs constitute a low percentage of sales. Nomura echoed this sentiment, stating market reactions were overblown and maintaining a Buy rating on JD HEALTH with a target price of HKD67.

- JD HEALTH and ALI HEALTH experienced stock declines due to market concerns over new regulations requiring paper prescriptions for GLP-1 drugs in Shanghai.  
- Despite these concerns, current regulations still permit online sales of diabetes drugs, and both companies reported no operational changes or regulatory instructions.  
- Analysts believe that even if restrictions expand, the financial impact will be manageable, as GLP-1 drug sales represent a low single-digit percentage of overall sales for both firms.

Nomura Holdings, Inc.

Nomura

ALI HEALTH  and JD HEALTH Drop 3%-5% as CLSA Says Impact from GLP-1 Online Sales Restrictions Limited; Nomura: Market Overreacted

Alibaba Health Information Technology Limited reported disappointing earnings, missing EPS expectations by 14% and revenue by 2.6%. Analysts have revised their forecasts, predicting a revenue increase to CN¥39.0b in 2027, reflecting a 14% growth. The consensus price target remains at HK$6.38, despite a wide range of analyst estimates. Concerns arise from reduced EPS estimates, indicating potential business challenges ahead, while revenue growth is expected to align with industry trends.

Simplywall

Earnings Miss: Alibaba Health Information Technology Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Alibaba Health reported a 12% revenue increase to RMB34.26B and a 35.2% rise in net profit to RMB1.94B, driven by direct sales, digital services, and new medical AI models. CFO Tu Yanwu has resigned, with no details on succession provided, raising concerns about leadership risk. The company will pay a final special dividend by reducing its share premium account balance.

TradingView

Key facts: Alibaba Health 34.26B rev; net +35% to 1.94B; CFO exits; dividend via premium

01889

588130

159837

Sanai Health Industry Group has been ordered by the High People’s Court of Beijing to pay approximately RMB120 million in a finance lease dispute involving its subsidiary, Fujian Sanai. The judgment includes principal, interest, and legal fees, with the company and two individuals held jointly liable. While this litigation will impact the company's cash reserves and net assets, Sanai Health has sufficient funds to cover the judgment. The management is evaluating the effects on its 2026 financial statements and plans to seek compensation from other parties involved.

SANAI HEALTH GP

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Sanai Health Hit With Final RMB120 Million Judgment in Beijing Lease Dispute

ALI HEALTHhas proposed to reduce its share premium by approximately RMB10 billion to fund a total dividend of RMB19.47 cents per share, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents. This decision comes as the company faces insufficient contributed surplus for distribution as of March 31, 2026. The reduction will allow the company to offset accumulated losses and distribute funds to shareholders.

ALI HEALTH Proposes to Reduce RMB10B Share Premium to Fund Dividend

ALI HEALTHreported a net profit of RMB1.94 billion for the year ending March 31, 2026, marking a 35.2% increase year-on-year. Revenue rose to RMB34.255 billion, up 12% YoY, with an EPS of RMB12.02 cents. The company declared a total dividend of RMB19.47 cents, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents.

ALI HEALTH Annual Net Profit RMB1.94B, Up 35.2% YoY; Final & Spec. Div. Total RMB19.47 Cents

China Universal 800 Health Care ETF(159929.SZ)